The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Combination therapies in myelofibrosis
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, reviews emerging combination strategies for myelofibrosis, including ruxolitinib-based regimens with selinexor, pelabresib, and navtemadlin, as well as momelotinib combinations. He discusses which patients may benefit most and how these approaches could improve spleen responses, anemia, and long-term outcomes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think there are three or four major combination therapies in MF. One of those is surely represented by ruxolitinib plus selinexor. I think we are having very good results both in terms of SVR and in terms of initial, very early sign of survival, they have to be confirmed because it’s a very early sign at the 24th week. But we are confident that probably patients with intermediate to high risk can really benefit from a combo...
I think there are three or four major combination therapies in MF. One of those is surely represented by ruxolitinib plus selinexor. I think we are having very good results both in terms of SVR and in terms of initial, very early sign of survival, they have to be confirmed because it’s a very early sign at the 24th week. But we are confident that probably patients with intermediate to high risk can really benefit from a combo. And it could be also an interesting proposal for those who will need to speed up their spleen response. Another drug that might be combined to drugs to increase the rate of SVR is surely pelabresib and we have long-term data showing that. Then there are some interesting exploratory combinations. One is in the phase 3 as well and it’s represented and devised as an add-on to ruxolitinib for those who are experiencing a suboptimal response or for those who are not responding to ruxolitinib and the add-on of navtemadlin can increase the apoptotic pathways in order to make the patient feel better and have major spleen responses. The fourth one I would like to mention is a phase one and it’s a combination between momelotinib and navtemadlin and patients who are cytopenic with anemia can benefit from that because the hematological toxicity seems to be very low.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
